Nonsmall cell adenocarcinoma.

But starting in 2004, when antiangiogenic therapies first became available, you can see that there has been a 70 to 100 percent improvement in survival for people with kidney cancer, multiple myeloma, colorectal cancer, and gastrointestinal stromal tumors.

Now, in Walt's case, with a stage llI adenocarcinoma I'd like to see, I hope to see at least a 25 to 35percent reduction in tumor mass something to tell me that the cancer has responded to the therapy.